𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry

✍ Scribed by Quijano, S.; Lopez, A.; Manuel Sancho, J.; Panizo, C.; Deben, G.; Castilla, C.; Antonio Garcia-Vela, J.; Salar, A.; Alonso-Vence, N.; Gonzalez-Barca, E.; Penalver, F. J.; Plaza-Villa, J.; Morado, M.; Garcia-Marco, J.; Arias, J.; Briones, J.; Ferrer, S.; Capote, J.; Nicolas, C.; Orfao, A.


Book ID
121856489
Publisher
American Society of Clinical Oncology
Year
2009
Tongue
English
Weight
182 KB
Volume
27
Category
Article
ISSN
0732-183X

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Critical role of multidimensional flow c
✍ R. Di Noto; G. Scalia; G. Abate; M. Gorrese; C. Pascariello; M. Raia; P. Morabit πŸ“‚ Article πŸ“… 2008 πŸ› Elsevier Science 🌐 English βš– 600 KB

Among histological aggressive non-Hodgkin lymphomas (NHL), the overall risk of central nervous system (CNS) relapse is approximately 5%, a figure which is too low to offer prophylaxis to all patients. The aim of this work is to demonstrate the utility of flow cytometry (FCM) in detecting occult lept

Prognostic significance of flow cytometr
✍ Suzanne Rehn; Bengt Glimelius; Peter Strang; Christer SundstrΓΆm; Bernhard Tribuk πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 711 KB

The prognostic relevance of flow cytometric DNA measurements of lymph node biopsies in relation to histopathology according to the Kiel classification, stage, age and presence or absence of B-symptoms was investigated in 106 patients with non-Hodgkin lymphomas (NHL) of proven B-cell type. Biopsies w

Cell kinetic analysis of non-Hodgkin's l
✍ Martin Erlanson; Jack Lindh; BjΓΆrn Zackrisson; GΓΆran Landberg; GΓΆran Roos πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 746 KB

The aim of this study was to analyse dynamic cell proliferation parameters in non-Hodgkin's lymphomas. Sixty-one patients with newly diagnosed or with recurrent disease were given iododeoxyuridine (IdUrd) intravenously near 4 h prior to tumour biopsy. After staining with an IdUrd reactive antibody a